Changelog Interviews From GitLab to Kilo Code
30 snips
Jan 7, 2026 
Sid Sijbrandij, founder of GitLab and now building Kilo, shares his journey from leading GitLab to navigating his cancer diagnosis. He discusses innovative cancer treatments, revealing how single-cell sequencing has impacted his health strategy. Sid describes his vision for Kilo as an all-in-one engineering platform, prioritizing open-source collaboration. With a focus on developing rapid AI-driven tools, he highlights a future where technology aids diagnostics and empowers aspiring developers. Amid his health challenges, Sid continues to inspire with his entrepreneurial spirit.
AI Snips
Chapters
Transcript
Episode notes
Flash-Freeze Tumor Tissue For Future Tests
- Preserve surgical tissue by flash-freezing to enable extensive later diagnostics instead of standard FFPE preservation.
- Use advanced diagnostics like single-cell sequencing and RNA expression to identify actionable targets.
Immunotherapy Created A Therapeutic Ladder
- Sid's tumor showed a jump in T-cell infiltration after checkpoint inhibitors and an oncolytic virus, indicating immune activation.
- He treats immunotherapy as part of a ladder that buys time for potentially curative options like an mRNA vaccine.
All-In-One Agentic Coding Platform
- Kilo aims to be an all-in-one open-source agentic coding platform covering coding, reviews, security, and deployment.
- Sid applies the GitLab playbook: single app, transparency, and rapid iteration to capture the full developer lifecycle.